RAPP Rapport Therapeutics, Inc.
Research report · from SEC EDGAR · close 2026-07-13
$40.59 -2.8%
$1.94B mkt cap
executive summary
Rapport Therapeutics, Inc. (RAPP) is a $1.94B company. It is not yet profitable. Our health score is A (88/100). 2 red flags on file. It funds itself; low dilution risk.
⚠Active dilution shelf
An effective S-3 shelf with 3 prospectus filing(s) in 12 months — shares may be getting sold into the market.
⚠One-sided insider selling
14 insider sales and no open-market buys in the recent window.
who's buying
Insider buys / sells
0 / 14
Cash & ST investments
$476.8M
Operating cash flow
-$87.5M
Dilution shelf
active shelf
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated 2026-07-13 by stocktools.ai.